日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

在类风湿性关节炎患者中，从原研英夫利昔单抗换用生物类似药SB2与继续使用原研英夫利昔单抗和SB2相比，其安全性、免疫原性和疗效：一项随机、双盲、III期过渡研究的结果

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2017-211741
Smolen, Josef S; Choe, Jung-Yoon; Prodanovic, Nenad; Niebrzydowski, Jaroslaw; Staykov, Ivan; Dokoupilova, Eva; Baranauskaite, Asta; Yatsyshyn, Roman; Mekic, Mevludin; Porawska, Wieslawa; Ciferska, Hana; Jedrychowicz-Rosiak, Krystyna; Zielinska, Agnieszka; Lee, Younju; Rho, Young Hee
关节炎
免疫/内分泌
发表日期：2018
文献求助 收藏

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results

在类风湿性关节炎患者中，从参考药物阿达木单抗转换为SB5（阿达木单抗生物类似药）：一项为期52周的III期随机研究结果

期刊:Arthritis & Rheumatology
影响因子:10.9
doi:10.1002/art.40444
Weinblatt, Michael E; Baranauskaite, Asta; Dokoupilova, Eva; Zielinska, Agnieszka; Jaworski, Janusz; Racewicz, Artur; Pileckyte, Margarita; Jedrychowicz-Rosiak, Krystyna; Baek, Inyoung; Ghil, Jeehoon
关节炎
发表日期：2018
文献求助 收藏

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis

SB5（一种阿达木单抗生物类似药）与参考阿达木单抗治疗中重度类风湿性关节炎患者的III期随机研究

期刊:Arthritis & Rheumatology
影响因子:10.9
doi:10.1002/art.40336
Weinblatt, Michael E; Baranauskaite, Asta; Niebrzydowski, Jaroslaw; Dokoupilova, Eva; Zielinska, Agnieszka; Jaworski, Janusz; Racewicz, Artur; Pileckyte, Margarita; Jedrychowicz-Rosiak, Krystyna; Cheong, Soo Yeon; Ghil, Jeehoon
关节炎
发表日期：2018
文献求助 收藏

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

一项随机、双盲、III期研究比较了英夫利昔单抗生物类似药SB2与英夫利昔单抗参考产品Remicade在接受甲氨蝶呤治疗后仍患有中重度类风湿性关节炎的患者中的疗效。

期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1136/annrheumdis-2015-207764
Choe, Jung-Yoon; Prodanovic, Nenad; Niebrzydowski, Jaroslaw; Staykov, Ivan; Dokoupilova, Eva; Baranauskaite, Asta; Yatsyshyn, Roman; Mekic, Mevludin; Porawska, Wieskawa; Ciferska, Hana; Jedrychowicz-Rosiak, Krystyna; Zielinska, Agnieszka; Choi, Jasmine; Rho, Young Hee; Smolen, Josef S
关节炎
发表日期：2017
文献求助 收藏

Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results

一项为期 54 周的双盲试验比较了生物类似药 SB2 与参考药物英夫利昔单抗：临床、结构和安全性结果

期刊:Rheumatology
影响因子:4.4
doi:10.1093/rheumatology/kex254
Smolen, Josef S; Choe, Jung-Yoon; Prodanovic, Nenad; Niebrzydowski, Jaroslaw; Staykov, Ivan; Dokoupilova, Eva; Baranauskaite, Asta; Yatsyshyn, Roman; Mekic, Mevludin; Porawska, Wieskawa; Ciferska, Hana; Jedrychowicz-Rosiak, Krystyna; Zielinska, Agnieszka; Choi, Jasmine; Rho, Young Hee
发表日期：2017
文献求助 收藏